ArticleBrain : a journal of neurology2025

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.

Caroline M Kopruszinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.